OBJECTIVES: To test the bactericidal activity of human beta-defensins (hBDs) 2 and 3 against extended-spectrum beta-lactamase (ESBL)-producing Klebsiella strains. METHODS: Thirty-six Klebsiella pneumoniae and seventeen Klebsiella oxytoca ESBL-producing isolates from nosocomial infections were tested. The bactericidal activity of recombinantly synthesized hBD-2 and -3 was tested and the results were given either as lethal doses killing > or = 90% of bacteria (LD90s) or as MBCs (> or = 99.9% killing). RESULTS: Except for one intermediately susceptible strain (MBC = 25 mg/L), all other ESBL-producing strains were highly susceptible to both defensins (LD90s and MBCs < or = 12.5 mg/L). CONCLUSIONS: The results underline the high efficacy of hBD-2 and -3 against ESBL-producing Klebsiella, making both defensins attractive candidates as antimicrobial agents to combat these increasingly troublesome bacteria.
OBJECTIVES: To test the bactericidal activity of humanbeta-defensins (hBDs) 2 and 3 against extended-spectrum beta-lactamase (ESBL)-producing Klebsiella strains. METHODS: Thirty-six Klebsiella pneumoniae and seventeen Klebsiella oxytocaESBL-producing isolates from nosocomial infections were tested. The bactericidal activity of recombinantly synthesized hBD-2 and -3 was tested and the results were given either as lethal doses killing > or = 90% of bacteria (LD90s) or as MBCs (> or = 99.9% killing). RESULTS: Except for one intermediately susceptible strain (MBC = 25 mg/L), all other ESBL-producing strains were highly susceptible to both defensins (LD90s and MBCs < or = 12.5 mg/L). CONCLUSIONS: The results underline the high efficacy of hBD-2 and -3 against ESBL-producing Klebsiella, making both defensins attractive candidates as antimicrobial agents to combat these increasingly troublesome bacteria.
Authors: Carlos H Serezani; Jooho Chung; Megan N Ballinger; Bethany B Moore; David M Aronoff; Marc Peters-Golden Journal: Am J Respir Cell Mol Biol Date: 2007-06-21 Impact factor: 6.914
Authors: Malte Book; QiXing Chen; Lutz E Lehmann; Sven Klaschik; Stefan Weber; Jens-Christian Schewe; Markus Luepertz; Andreas Hoeft; Frank Stuber Journal: Crit Care Date: 2007 Impact factor: 9.097